9787687

Source:http://linkedlifedata.com/resource/pubmed/id/9787687

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008059, umls-concept:C0012133, umls-concept:C0019704, umls-concept:C0021311, umls-concept:C0034656, umls-concept:C0205195, umls-concept:C0231220, umls-concept:C0237967, umls-concept:C0442711, umls-concept:C0871489, umls-concept:C1318970, umls-concept:C2603343
pubmed:issue	4
pubmed:dateCreated	1998-11-25
pubmed:abstractText	The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 300 assessed the clinical efficacy and safety of combination zidovudine/lamivudine (ZDV/3TC) compared with either didanosine (ddI) alone or combination ZDV/ddI.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0375410
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4, http://linkedlifedata.com/resource/pubmed/chemical/Didanosine, http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0022-3476
pubmed:author	pubmed-author:BrouwersPP, pubmed-author:JohnsonG MGM, pubmed-author:KellerAA, pubmed-author:McKinneyR EREJr, pubmed-author:McNamaraJJ, pubmed-author:MitchellW GWG, pubmed-author:MofensonLL, pubmed-author:O'DonnellK JKJ, pubmed-author:SpectorS ASA, pubmed-author:StanleyKK, pubmed-author:WaraD WDW, pubmed-author:WizniaAA, pubmed-author:YogevRR, pubmed-author:ZangW JWJ
pubmed:issnType	Print
pubmed:volume	133
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	500-8
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:9787687-Adolescent, pubmed-meshheading:9787687-Anti-HIV Agents, pubmed-meshheading:9787687-Antigens, CD4, pubmed-meshheading:9787687-Child, pubmed-meshheading:9787687-Child, Preschool, pubmed-meshheading:9787687-Didanosine, pubmed-meshheading:9787687-Disease Progression, pubmed-meshheading:9787687-Double-Blind Method, pubmed-meshheading:9787687-Drug Therapy, Combination, pubmed-meshheading:9787687-Female, pubmed-meshheading:9787687-Follow-Up Studies, pubmed-meshheading:9787687-HIV Infections, pubmed-meshheading:9787687-HIV-1, pubmed-meshheading:9787687-Humans, pubmed-meshheading:9787687-Lamivudine, pubmed-meshheading:9787687-Male, pubmed-meshheading:9787687-Neurodegenerative Diseases, pubmed-meshheading:9787687-Polymerase Chain Reaction, pubmed-meshheading:9787687-RNA, Viral, pubmed-meshheading:9787687-Survival Rate, pubmed-meshheading:9787687-Zidovudine
pubmed:year	1998
pubmed:articleTitle	A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
pubmed:affiliation	Department of Pediatrics and Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study